News
Real-world experience in nearly 20,000 patients with the Allurion Program confirms significant fat loss while increasing lean body and muscle mass In one of the longest real-world studies of its kind, ...
Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS Findings from two ...
Shares of Allurion Technologies rallied after the company said patients lost weight and maintained muscle mass while using its Allurion Balloon and AI-Powered Virtual Care Suite. The stock rose 42 ...
Four abstracts presented at the European Congress on Obesity Data indicate potential synergies of Allurion’s swallowable ProcedurelessTM intragastric balloon (the "Allurion Balloon") and Virtual Care ...
Data indicate potential synergies of Allurion’s swallowable Procedureless TM intragastric balloon (the "Allurion Balloon") and Virtual Care Suite (VCS) (together, the "Allurion Program") with ...
ALUR opened at $3.60 on Monday. The firm has a market capitalization of $17.24 million, a PE ratio of -0.30 and a beta of -0.59. Allurion Technologies has a twelve month low of $2.15 and a twelve ...
Allurion swallowable balloon Nik Ritza notes that an increasing number of people are now opting for an innovative, non-invasive treatment – the swallowable intragastric balloon (IGB).
Photo by Jeslyn Teh. The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's stomach endoscopically before being expanded with 550 milliliters of water. Aqilah Yunus ...
In Malaysia, cases of overweight and obesity are now increasing at an alarming rate. Photo by Jeslyn Teh. The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's ...
The AUDACITY trial is an open-label, multicenter, randomized, controlled study and is the first FDA pivotal trial on an intragastric balloon for weight loss to report primary outcomes beyond 9 months.
Additionally, the trial reported a low rate of serious adverse events at 3.1%, marking it as the lowest in a pivotal FDA trial for a liquid-filled intragastric balloon. Dr. Shelby Sullivan, Lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results